ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS


Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with relapsing multiple sclerosis (MS) in high disease activity subgroups with no evidence of disease activity (NEDA) compared with placebo (43.7% vs. 8.7%). The company also shared late-breaking safety analyses including patients with up to eight-years follow-up from monotherapy oral (3.5 mg/kg) cohorts reinforcing safety conclusions of the earlier meta-analysis, as well as an analysis of T lymphocyte (T cells) subpopulations from the ORACLE-MS study demonstrating changes that occur in the adaptive immune system following Cladribine Tablets treatment.


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.